These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20851921)

  • 1. Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis.
    Henriksen K; Bollerslev J; Everts V; Karsdal MA
    Endocr Rev; 2011 Feb; 32(1):31-63. PubMed ID: 20851921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
    Tanaka S
    Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of osteoclast function and pathways.
    Broadhead ML; Clark JC; Dass CR; Choong PF; Myers DE
    Expert Opin Ther Targets; 2011 Feb; 15(2):169-81. PubMed ID: 21204734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K
    Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent insights into the biology of bone turnover.
    Riches PL; Ralston SH
    J R Coll Physicians Edinb; 2010 Mar; 40(1):66-9. PubMed ID: 21125043
    [No Abstract]   [Full Text] [Related]  

  • 7. Communication factors-promising targets in osteoporosis treatment.
    Zhang Y; Liu P; Li J; Li K; Teng Y; Wang X; Li X
    Curr Drug Targets; 2014 Feb; 15(2):156-63. PubMed ID: 23919828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future developments in osteoporosis therapy.
    Ng KW
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):371-84. PubMed ID: 19857200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miconazole inhibits receptor activator of nuclear factor-κB ligand-mediated osteoclast formation and function.
    Zheng T; Wang X; Yim M
    Eur J Pharmacol; 2014 Aug; 737():185-93. PubMed ID: 24842191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are nonresorbing osteoclasts sources of bone anabolic activity?
    Karsdal MA; Martin TJ; Bollerslev J; Christiansen C; Henriksen K
    J Bone Miner Res; 2007 Apr; 22(4):487-94. PubMed ID: 17227224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo.
    Kukita A; Kukita T; Nagata K; Teramachi J; Li YJ; Yoshida H; Miyamoto H; Gay S; Pessler F; Shobuike T
    Arthritis Rheum; 2011 Sep; 63(9):2744-54. PubMed ID: 21590684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
    Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
    Hughes A; Rogers MJ; Idris AI; Crockett JC
    Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of the osteoclastogenic RANKL-RANK axis prevents osteoporotic bone loss and soft tissue calcification in coxsackievirus B3-infected mice.
    Lee K; Kim H; Park HS; Kim KJ; Song H; Shin HI; Kim HS; Seo D; Kook H; Ko JH; Jeong D
    J Immunol; 2013 Feb; 190(4):1623-30. PubMed ID: 23303667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology.
    Narducci P; Bareggi R; Nicolin V
    Acta Histochem; 2011 Feb; 113(2):73-81. PubMed ID: 19926120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclast culture and resorption assays.
    Bradley EW; Oursler MJ
    Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
    Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
    Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
    Romas E
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.